USMLE Step 1 Quiz
Practice Endocrine Pharmacology in USMLE Step 1 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
Question 1 / 20
0 of 20 answered
A 55-year-old man with a BMI of 32 kg/m² is newly diagnosed with type 2 diabetes mellitus. His initial HbA1c is 7.8%. In addition to lifestyle modifications, he is started on a first-line oral medication. He has no history of heart failure or chronic kidney disease.
Which of the following best describes the primary mechanism of action of the medication prescribed for this patient?
This quiz focuses on Endocrine Pharmacology, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 1.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A 55-year-old man with a BMI of 32 kg/m² is newly diagnosed with type 2 diabetes mellitus. His initial HbA1c is 7.8%. In addition to lifestyle modifications, he is started on a first-line oral medication. He has no history of heart failure or chronic kidney disease.
Which of the following best describes the primary mechanism of action of the medication prescribed for this patient?
Explanation: The first-line oral agent for type 2 diabetes mellitus is metformin. Metformin's primary mechanism of action is the inhibition of hepatic gluconeogenesis. It also increases peripheral glucose uptake and insulin sensitivity, but its main effect is on the liver. The other options describe different classes of antidiabetic drugs: sulfonylureas (B), thiazolidinediones (C), and SGLT2 inhibitors (D).
A 60-year-old man with type 2 diabetes and coronary artery disease is started on a new oral medication to improve his glycemic control. Three months later, he presents to his physician complaining of a 5-kg weight gain and new-onset swelling in his feet and ankles. Physical examination confirms 2+ pitting edema of the lower extremities.
The medication responsible for these findings most likely acts by which of the following mechanisms?
Explanation: Weight gain and fluid retention leading to peripheral edema are characteristic side effects of thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone. These drugs act as agonists for the peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor that increases insulin sensitivity in adipose tissue, muscle, and liver. Fluid retention is a major concern, especially in patients with heart failure.
A 67-year-old man with type 2 diabetes and a history of atherosclerotic cardiovascular disease is started on canagliflozin. His physician explains that this medication has been shown to have cardiovascular benefits in patients like him. The patient is counseled on potential side effects.
An increased risk for which of the following conditions is most associated with this patient's new medication?
Explanation: Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. These drugs block glucose reabsorption in the proximal renal tubule, leading to glucosuria. The increased glucose in the urine creates a favorable environment for microbial growth, significantly increasing the risk of urinary tract infections and vulvovaginal candidiasis. Lactic acidosis is associated with metformin (B). Agranulocytosis is a rare side effect of thionamides (C). Pancreatitis is a concern with GLP-1 agonists and DPP-4 inhibitors (D).
A 45-year-old woman is diagnosed with primary hypothyroidism due to Hashimoto thyroiditis. She is started on levothyroxine. Her follow-up laboratory tests are scheduled in 6 weeks to assess the adequacy of the initial dose.
Effective therapy with this medication will most likely result in which of the following changes in her thyroid function tests?
Explanation: In primary hypothyroidism, the thyroid gland fails, leading to low T4 and a compensatory increase in TSH from the pituitary. Levothyroxine is synthetic T4. Treatment replaces the deficient hormone, increasing free T4 levels. The increased T4 provides negative feedback to the pituitary, which suppresses TSH secretion, bringing it back down into the normal range. Therefore, successful treatment is marked by a decrease in TSH and an increase in free T4.
A 28-year-old woman is diagnosed with Graves disease after presenting with palpitations, heat intolerance, and a 6-kg weight loss. She is started on methimazole to control her symptoms before definitive therapy.
This medication primarily reduces thyroid hormone levels by inhibiting which of the following processes?
Explanation: Methimazole is a thionamide drug that inhibits thyroid peroxidase (TPO). TPO is the key enzyme in thyroid hormone synthesis, responsible for oxidizing iodide to iodine and then incorporating it into tyrosine residues on thyroglobulin (organification). By blocking TPO, methimazole effectively halts the synthesis of new thyroid hormone. It does not block the peripheral conversion of T4 to T3 (B), a property unique to PTU. Iodide uptake (C) is blocked by perchlorate. Release of preformed hormone (D) is inhibited by high doses of iodine.
A 65-year-old man with a severe exacerbation of chronic obstructive pulmonary disease is treated with a 10-day course of high-dose oral prednisone. During his hospital stay, his morning fingerstick glucose levels are consistently elevated in the 180-220 mg/dL range, despite having no prior history of diabetes.
Which of the following is the most likely mechanism responsible for this patient's hyperglycemia?
Explanation: Glucocorticoids, such as prednisone, are well-known to cause hyperglycemia. They do so by multiple mechanisms: they stimulate hepatic gluconeogenesis and glycogenolysis, and they decrease peripheral glucose uptake and utilization by muscle and adipose tissue, creating a state of insulin resistance. Autoimmune destruction of beta cells (B) is the cause of type 1 diabetes. Glucocorticoids increase glucagon secretion (C) and decrease, rather than enhance, peripheral glucose uptake (D).
A 52-year-old woman has been taking prednisone 20 mg daily for the past 6 months to manage her rheumatoid arthritis. She decides to stop her medication abruptly because she is feeling better. Two days later, she presents to the emergency department with nausea, vomiting, hypotension, and weakness.
This patient's acute presentation is a direct consequence of the suppression of which of the following?
Explanation: Prolonged use of exogenous glucocorticoids (e.g., prednisone for >3 weeks) suppresses the HPA axis through negative feedback on the hypothalamus (CRH) and pituitary (ACTH). This leads to adrenal cortex atrophy. Abrupt cessation of the steroid unmasks this suppression, resulting in an iatrogenic acute adrenal insufficiency (adrenal crisis) because the atrophied adrenal glands cannot produce enough endogenous cortisol to meet physiologic demands.
A 38-year-old woman is found to have hypertension and hypokalemia. Further workup reveals an aldosterone-secreting adrenal adenoma (Conn syndrome). She is started on spironolactone while awaiting surgery. At her follow-up visit, she complains of breast tenderness and menstrual irregularities.
These side effects are primarily due to the drug's activity at which of the following non-target receptors?
Explanation: Spironolactone is a potassium-sparing diuretic that acts as a competitive antagonist of the mineralocorticoid (aldosterone) receptor. However, its structure is similar to sex hormones, and it is non-selective, also acting as an antagonist at androgen receptors and an agonist at progesterone receptors. Its antiandrogenic effects can cause gynecomastia, decreased libido, and impotence in men, and its progestogenic effects can cause breast tenderness and menstrual irregularities in women.
A 25-year-old man who sustained a severe head injury in a motor vehicle accident develops polyuria and hypernatremia. A water deprivation test followed by administration of desmopressin shows a significant increase in urine osmolality and a decrease in urine output. He is started on long-term therapy with intranasal desmopressin.
This medication improves the patient's symptoms by acting as a selective agonist at which of the following receptors?
Explanation: The patient has central diabetes insipidus, characterized by a deficiency of antidiuretic hormone (ADH, or vasopressin). Desmopressin (DDAVP) is a synthetic analog of ADH with high selectivity for the V2 receptor and minimal activity at the V1a receptor. Activation of V2 receptors in the principal cells of the renal collecting ducts stimulates the insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and concentrating the urine.
A 68-year-old woman with postmenopausal osteoporosis is prescribed alendronate. Her pharmacist counsels her to take the medication first thing in the morning with a full glass of water and to remain upright for at least 30 minutes after swallowing the pill.
The primary mechanism by which this medication increases bone mineral density is by which of the following actions?
Explanation: Alendronate is a bisphosphonate. Bisphosphonates are pyrophosphate analogs that bind to hydroxyapatite in bone. They are taken up by osteoclasts during bone resorption. Inside the osteoclast, they inhibit farnesyl pyrophosphate synthase, disrupting a key metabolic pathway and inducing osteoclast apoptosis. This reduces bone resorption, allowing osteoblastic activity to predominate, thereby increasing bone mineral density. The specific administration instructions are to prevent esophagitis, a major side effect.
A 45-year-old man with acromegaly due to a growth hormone-secreting pituitary adenoma undergoes transsphenoidal surgery. Postoperatively, his IGF-1 levels remain elevated. He is started on monthly intramuscular injections of a long-acting medication to control his symptoms and hormone levels.
This medication most likely exerts its therapeutic effect by mimicking the action of which endogenous substance?
Explanation: The treatment described is a somatostatin analog, such as octreotide or lanreotide. Somatostatin is a natural hormone that inhibits the release of many other hormones, including growth hormone (GH) from the anterior pituitary. By activating somatostatin receptors on the pituitary adenoma, these drugs suppress GH secretion, which in turn lowers the production of IGF-1 in the liver, thereby controlling the clinical manifestations of acromegaly.
A 32-year-old woman presents with a 6-month history of amenorrhea and milky discharge from her nipples. Laboratory studies show a serum prolactin level of 150 ng/mL (normal <25 ng/mL). An MRI of the brain reveals a 6-mm pituitary microadenoma. She is started on cabergoline.
The therapeutic effect of this medication is mediated through its agonist activity at which of the following receptors?
Explanation: The patient has a prolactinoma. Prolactin secretion from lactotroph cells in the anterior pituitary is tonically inhibited by dopamine from the hypothalamus. Cabergoline is a potent dopamine D2 receptor agonist. By stimulating D2 receptors on the prolactinoma cells, it mimics the natural inhibitory effect of dopamine, leading to decreased prolactin synthesis and secretion, which restores normal menstrual function and resolves the galactorrhea.
A 68-year-old man with metastatic prostate cancer is started on leuprolide as part of his androgen deprivation therapy. His urologist explains that there might be a temporary worsening of his symptoms, like bone pain, during the first week of treatment.
What is the mechanism by which continuous administration of leuprolide ultimately leads to decreased testosterone production?
Explanation: Leuprolide is a GnRH agonist. Initially, it stimulates GnRH receptors, causing a transient surge in LH and FSH, which leads to a temporary increase in testosterone (explaining the initial 'flare'). However, continuous, non-pulsatile stimulation of the pituitary gonadotrophs leads to downregulation and desensitization of the GnRH receptors. This ultimately results in decreased LH and FSH secretion and subsequent suppression of testicular testosterone production to castrate levels.
A 70-year-old woman with type 2 diabetes is prescribed sitagliptin as an add-on therapy to metformin. Her physician explains that this oral medication works by enhancing the body's natural hormonal response to eating a meal.
The primary mechanism of action of this drug is to increase the half-life of which of the following endogenous substances?
Explanation: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The enzyme DPP-4 is responsible for the rapid degradation of incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, sitagliptin increases the half-life and circulating levels of these endogenous incretins. This enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, particularly after a meal.
A 22-year-old man with type 1 diabetes is transitioned to an insulin pump for better glycemic control. For his basal insulin coverage, he previously took a once-daily injection of insulin glargine. This insulin formulation provides a relatively peakless, long-lasting effect.
Which of the following properties of insulin glargine is primarily responsible for its prolonged duration of action?
Explanation: Insulin glargine is a long-acting insulin analog formulated at an acidic pH (pH 4.0), at which it is soluble. When injected into the neutral pH (~7.4) of the subcutaneous tissue, it precipitates. These microprecipitates slowly dissolve over time, releasing insulin monomers into the circulation at a steady, prolonged rate, resulting in a peakless profile that lasts approximately 24 hours. Binding to albumin (B) and attachment of a fatty acid chain (D) are mechanisms for insulin detemir and degludec. Formation of hexamers with protamine (C) is the mechanism for NPH insulin.
A 40-year-old man with primary adrenal insufficiency (Addison disease) is managed with hydrocortisone. Despite this, he continues to experience salt craving, postural hypotension, and his labs show a serum potassium of 5.6 mEq/L. His physician adds fludrocortisone to his regimen.
The addition of fludrocortisone is intended to replace the activity of which of the following deficient hormones?
Explanation: Primary adrenal insufficiency involves destruction of the adrenal cortex, leading to a deficiency of both glucocorticoids (cortisol) and mineralocorticoids (aldosterone). Hydrocortisone replaces cortisol but has insufficient mineralocorticoid activity at physiologic doses. The patient's symptoms of hypotension, salt craving, and hyperkalemia are due to aldosterone deficiency. Fludrocortisone is a potent synthetic mineralocorticoid that acts like aldosterone to increase renal sodium reabsorption and potassium excretion, thereby restoring volume and correcting electrolyte abnormalities.
A 30-year-old woman in her 10th week of gestation is diagnosed with hyperthyroidism. Her physician elects to start propylthiouracil (PTU). In addition to inhibiting thyroid hormone synthesis, this drug is chosen for its unique peripheral mechanism of action.
Which of the following additional mechanisms is characteristic of propylthiouracil but not methimazole?
Explanation: Both propylthiouracil (PTU) and methimazole inhibit thyroid peroxidase. However, a key difference is that PTU also inhibits the 5'-deiodinase enzyme, which is responsible for the peripheral conversion of the prohormone T4 to the more biologically active T3. This additional mechanism contributes to a more rapid decrease in active thyroid hormone levels, making it useful in thyroid storm. Methimazole lacks this peripheral effect.
A 72-year-old woman with severe osteoporosis has sustained two vertebral compression fractures in the past year despite being on bisphosphonate therapy. Her physician decides to switch her to a daily subcutaneous injection of teriparatide.
In contrast to bisphosphonates, which are anti-resorptive, teriparatide improves bone density through which of the following mechanisms?
Explanation: Teriparatide is a recombinant form of human parathyroid hormone (PTH). When administered intermittently (once-daily injection), it has a net anabolic effect on bone, directly stimulating osteoblast function and promoting new bone formation. This contrasts with the catabolic effect of continuously elevated PTH seen in hyperparathyroidism and the anti-resorptive mechanism of bisphosphonates. B describes the mechanism of denosumab (anti-RANKL). C describes raloxifene.
A 48-year-old obese woman with type 2 diabetes has not achieved her HbA1c goal despite being on maximum-dose metformin. Her physician adds a weekly subcutaneous injectable medication. In addition to improving her glycemic control, this medication is also known to promote weight loss.
Which of the following best describes the mechanism of action of this newly added medication?
Explanation: The description fits a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide or dulaglutide, which are often administered weekly. These drugs mimic the action of the incretin hormone GLP-1, leading to glucose-dependent insulin release, decreased glucagon secretion, delayed gastric emptying, and increased satiety, which frequently results in weight loss. A long-acting insulin (B) would cause weight gain. Amylin analogs like pramlintide (C) can cause weight loss but are less commonly used. DPP-4 inhibitors (D) are oral agents and are weight-neutral.
A 62-year-old woman with a long-standing history of type 2 diabetes is brought to the emergency department with confusion, sweating, and tremors. Her family reports that she may have accidentally taken an extra dose of her medication this morning. Her fingerstick glucose is 45 mg/dL. Her medications include metformin and glyburide.
The patient's hypoglycemic episode is most likely caused by a medication that acts via which of the following mechanisms?
Explanation: The patient is experiencing severe hypoglycemia, a well-known side effect of sulfonylureas like glyburide. Sulfonylureas exert their effect by binding to and closing the ATP-dependent potassium (K-ATP) channels on pancreatic beta cells. This leads to membrane depolarization, calcium influx, and glucose-independent insulin secretion, which carries a high risk of hypoglycemia. DPP-4 inhibitors (B) and GLP-1 agonists (C) have a low risk of hypoglycemia because their action is glucose-dependent. Metformin (D) does not typically cause hypoglycemia when used as monotherapy.